Clinical Trial Update: FloSeal in CRS and HIPEC

View source ↗

Summary

This clinical trial update reports on the use of FloSeal as a hemostatic agent during CRS with HIPEC for peritoneal carcinomatosis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Carcinomatosis

Drugs mentioned

• Floseal

Snippet

Sponsor: Maisonneuve-Rosemont Hospital | Conditions: Peritoneal Carcinomatosis | Status: COMPLETED